BCS Wealth Management Takes Position in Pfizer Inc. (NYSE:PFE)

BCS Wealth Management bought a new stake in Pfizer Inc. (NYSE:PFE) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 45,715 shares of the biopharmaceutical company’s stock, valued at approximately $1,213,000.

A number of other institutional investors have also modified their holdings of PFE. Gladius Capital Management LP increased its stake in Pfizer by 102.8% during the 3rd quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 38,015 shares during the period. Quarry LP acquired a new stake in Pfizer in the 2nd quarter valued at about $31,000. Teachers Insurance & Annuity Association of America purchased a new position in shares of Pfizer in the 3rd quarter valued at about $35,000. Joseph Group Capital Management grew its position in shares of Pfizer by 168.3% during the third quarter. Joseph Group Capital Management now owns 1,229 shares of the biopharmaceutical company’s stock worth $36,000 after buying an additional 771 shares in the last quarter. Finally, Kennebec Savings Bank purchased a new stake in shares of Pfizer during the third quarter worth approximately $50,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Price Performance

Shares of NYSE PFE opened at $26.79 on Tuesday. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The stock has a market cap of $151.82 billion, a P/E ratio of 36.20, a P/E/G ratio of 0.63 and a beta of 0.64. The stock has a 50 day moving average of $26.16 and a two-hundred day moving average of $28.04. Pfizer Inc. has a twelve month low of $24.48 and a twelve month high of $31.54.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, topping analysts’ consensus estimates of $0.64 by $0.42. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The firm had revenue of $17.70 billion during the quarter, compared to analysts’ expectations of $14.92 billion. During the same quarter in the prior year, the business earned ($0.17) EPS. Pfizer’s quarterly revenue was up 31.2% compared to the same quarter last year. On average, research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 6.42%. This is a boost from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date of this dividend is Friday, January 24th. Pfizer’s dividend payout ratio (DPR) is presently 232.43%.

Insider Buying and Selling at Pfizer

In other news, Director Scott Gottlieb purchased 1,000 shares of the company’s stock in a transaction dated Wednesday, October 30th. The shares were acquired at an average cost of $28.24 per share, for a total transaction of $28,240.00. Following the completion of the purchase, the director now directly owns 10,000 shares in the company, valued at $282,400. The trade was a 11.11 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.06% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently issued reports on PFE shares. Evercore ISI upgraded shares of Pfizer to a “strong-buy” rating in a research note on Wednesday, October 30th. Truist Financial lowered their target price on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research note on Wednesday, December 18th. Guggenheim decreased their price target on Pfizer from $35.00 to $33.00 and set a “buy” rating for the company in a report on Wednesday, December 11th. UBS Group lowered their price objective on Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research report on Wednesday, January 8th. Finally, Wolfe Research started coverage on Pfizer in a research report on Friday, November 15th. They set an “underperform” rating and a $25.00 target price on the stock. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $32.00.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.